OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
Branch entity
GIVN57

Givaudan SA

Specialty ChemicalsVerified

Givaudan maintains a fully diluted share count of 9,229,197 shares, with no dilution observed between basic and diluted shares, indicating no current dilutive instruments outstanding. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability metrics are not available in the valuation snapshot, and no industry_config preferred metrics are provided for comparison. This limits the ability to assess Givaudan’s returns relative to its peers in the Specialty Chemicals industry. Givaudan’s revenue is concentrated in its two core segments: Fragrances and Flavors. The company operates globally, with significant exposure to North America and Europe, though specific geographic revenue breakdowns are not disclosed in the available data. Outlook data is not provided in the input, and historical revenue growth rates are absent, making it difficult to assess the company’s growth trajectory. Analysts have issued a mean price target of 3,360.87 CHF, with a median of 3,250.00 CHF, suggesting a generally positive sentiment. Risk assessment indicates low dilution risk, but liquidity risk remains unassessed due to missing balance-sheet data. No dilution sources are explicitly cited in the input, and no adjustments are noted in the custom valuations. Recent events include analyst estimates and price targets, with 4 strong-buy, 5 buy, and 11 hold recommendations. No recent filings or transcripts are provided in the input to inform operational or strategic developments.

30-day price · GIVN(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyGivaudan SA
TickerGIVN.S
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustrySpecialty Chemicals
AI analysis

Business. Givaudan SA is a global leader in the development, production, and marketing of fragrances and flavorings, serving the consumer goods and food industries.

Classification. Givaudan is classified under the Basic Materials economic sector, Chemicals business sector, and Specialty Chemicals industry, with a high confidence level of 0.92 based on verified market data.

Givaudan maintains a fully diluted share count of 9,229,197 shares, with no dilution observed between basic and diluted shares, indicating no current dilutive instruments outstanding. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability metrics are not available in the valuation snapshot, and no industry_config preferred metrics are provided for comparison. This limits the ability to assess Givaudan’s returns relative to its peers in the Specialty Chemicals industry. Givaudan’s revenue is concentrated in its two core segments: Fragrances and Flavors. The company operates globally, with significant exposure to North America and Europe, though specific geographic revenue breakdowns are not disclosed in the available data. Outlook data is not provided in the input, and historical revenue growth rates are absent, making it difficult to assess the company’s growth trajectory. Analysts have issued a mean price target of 3,360.87 CHF, with a median of 3,250.00 CHF, suggesting a generally positive sentiment. Risk assessment indicates low dilution risk, but liquidity risk remains unassessed due to missing balance-sheet data. No dilution sources are explicitly cited in the input, and no adjustments are noted in the custom valuations. Recent events include analyst estimates and price targets, with 4 strong-buy, 5 buy, and 11 hold recommendations. No recent filings or transcripts are provided in the input to inform operational or strategic developments.
Key takeaways
  • Givaudan has no current dilutive instruments outstanding, as basic and diluted shares are equal.
  • Analysts have a generally positive outlook, with a mean price target of 3,360.87 CHF.
  • Liquidity risk could not be assessed due to missing balance-sheet data.
  • Revenue is concentrated in two core segments, with global geographic exposure.
  • No growth trajectory or historical revenue data is available for analysis.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCHF
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$6.68B$1.09B$821.0M$366.0M
FY-3$7.12B$1.11B$856.0M$309.0M
FY-2$6.92B$1.12B$893.0M$174.0M
FY-1$7.41B$1.39B$1.09B$529.0M
FY0$7.47B$1.38B$1.07B$490.0M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$11.43B$3.93B$1.0M
FY-3$11.51B$4.23B
FY-2$11.13B$3.99B
FY-1$12.10B$4.58B
FY0$11.86B$4.54B
PeriodOCFCapExFCFSBC
FY-4$1.29B-$256.0M$366.0M
FY-3$948.0M-$304.0M$309.0M
FY-2$1.37B-$458.0M$174.0M
FY-1$1.62B-$293.0M$529.0M
FY0$1.51B-$305.0M$490.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6$1.91B
FQ-5
FQ-4$1.98B
FQ-3
FQ-2$1.88B
FQ-1
FQ0$1.88B
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricGIVNActivity
Op margin5.5% medp25 -0.0% · p75 10.8%
Net margin4.1% medp25 0.1% · p75 8.8%
Gross margin20.5% medp25 12.4% · p75 29.7%
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-6.2% medp25 -13.4% · p75 -2.6%
Debt / equity37.1% medp25 10.3% · p75 82.0%
Observations
IR observations
Mean price target3,360.87 CHF
Median price target3,250.00 CHF
High price target4,500.00 CHF
Low price target2,600.00 CHF
Mean recommendation2.61 (1=strong buy, 5=strong sell)
Strong-buy count4.00
Buy count5.00
Hold count11.00
Sell count2.00
Strong-sell count1.00
Mean EPS estimate120.47 CHF
Last actual EPS119.12 CHF
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-01 06:50 UTC#2ff8d0d7
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 00:54 UTCJob: c87c682f